Supplementary Tables S1 to S15 from Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells

The Supplementary Tables file includes Tables S1 to S15. Table S1: Frequencies of CD34+CD38- LSCs within primary AML patient samples. Table S2: Immunopeptidomics cohort overview. Table S3: Patient characteristics of AML immunopeptidomics cohort. Table S4: AML- and AML/LSC-associated HLA class I targets. Table S5: AML/LSC shared HLA class I-presented antigens. Table S6: AML- and AML/LSC-associated HLA class II peptide, protein, and hotspot targets. Table S7: AML/LSC shared HLA class II-presented peptide targets. Table S8: Recurrent AML mutations included in neoepitope screening. Table S9: Characteristics of AML patient samples used for T cell-based assays. Table S10: Characteristics of HV samples used for T cell-based assays. Table S11: Immunopeptidome diversity according to demographics and disease characteristics. Table S12: Impact of demographics and disease characteristics on patient outcome in the immunopeptidome survival analysis group. Table S13: Patient characteristics of immunopeptidome survival analysis group. Table S14: Patient characteristics of immune response survival analysis group. Table S15: Impact of demographics and hematopoietic stem cell transplantation on patient outcome in the immune response survival group.